About
march.biosciences is a clinical-stage company developing CAR-T cell therapies targeting challenging hematological cancers, with a lead product MB-105 aimed at treating T-cell lymphoma.
Explore march.biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.